1 Title

	2	Association between health-related	d hope and adherence to	prescribed treatment in CKI
--	---	------------------------------------	-------------------------	-----------------------------

- 3 patients: multicenter cross-sectional study.
- 4 Running head: Health-related hope and adherence in CKD
- 5

6	Noriaki Kurita, MD, PhD, FACP ^{1,2,3} , Takafumi Wakita, PhD ⁴ , Yoshitaka Ishibashi, MD, PhD ⁵ ,
7	Shino Fujimoto, MSc ⁵ , Masahiko Yazawa, MD, PhD ⁶ , Tomo Suzuki, MD, PhD ^{6,7} , Kenichiro
8	Koitabashi, MD, PhD ⁶ , Mai Yanagi, MD ⁵ , Hiroo Kawarazaki, MD, PhD ^{6,8} , Joseph Green,
9	DMSc ⁹ , Shunichi Fukuhara, MD, DMSc, MACP ^{2,10,11} , Yugo Shibagaki, MD, PhD ⁶ .
10	
11	Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),
12	Fukushima Medical University Hospital, Fukushima, Japan ¹
13	Center for Innovative Research for Communities and Clinical Excellence (CIRC ² LE),
14	Fukushima Medical University, Fukushima, Japan ²
15	Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
16	University, Fukushima, Japan ³
17	Department of Sociology, Kansai University, Osaka, Japan ⁴
18	Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan ⁵
19	Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna

					6
1	I Laire and iter	Calcal	of Medicine,	Vanagarra	Laman
	University	SCHOOL	or weatche	K anagawa	Tapan
-	omverbity	Demoor	or meanenie,	Isunu ₅ u ⁿ u,	Jupun

					1
0		f NI 1 1	\mathbf{V}_{-}	Center, Chiba, Japan	2
•/	Lienartment (NE Nennrology	K ameda Medical	i enter i ning langn'	
Z	DUDarument		ixamuua muuuu	Conton. Cintua, Japan	

- 3 Department of Nephrology, Inagi Municipal Hospital, Tokyo, Japan⁸
- 4 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan⁹
- 5 Department of Healthcare Epidemiology, School of Public Health in the Graduate School of
- 6 Medicine, Kyoto University, Kyoto, Japan¹⁰
- 7 Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of
- 8 Medicine, Kyoto University¹¹
- 9
- 10 Word count for the abstract: 291 words
- 11 Word count for the manuscript: 3,242 words
- 12 Short title: hope and adherence in CKD
- 13
- 14 Address correspondence to: Noriaki Kurita, MD, PhD, FACP
- 15 Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
- 16 University
- 17 1 Hikarigaoka, Fukushima City
- 18 Fukushima 960-1295, Japan
- 19 **TEL:** +81-24-547-1471

1 FAX: +81-24-547-1468

E-mail: kuritanoriaki@gmail.com $\mathbf{2}$

- 3
- 4
- 5
- 6

1

2 Abstract

3	Backgroun	d
---	-----------	---

- 4 In chronic kidney disease (CKD), patients' adherence to prescriptions for diet and for
- 5 medications might depend on the degree to which they have hope that they will enjoy life, and
- 6 that hope could vary with the stage of CKD. The aims of this study were to quantify both the
- 7 association of CKD stage with health-related hope (HR-Hope), and the association of that
- 8 hope with psychological and physiological manifestations of adherence.
- 9
- 10 Methods
- 11 This was a cross-sectional study involving 461 adult CKD patients, some of whom were
- 12 receiving dialysis. Main exposure was HR-Hope, measured using a recently-developed
- 13 18-item scale. Outcomes were perceived burden of fluid restriction and of diet restriction,
- 14 measured using the KDQOL, and physiological manifestations of adherence (systolic and
- 15 diastolic blood pressure [BP], and serum phosphorus and potassium levels).
- 16 General linear models and generalized ordered logit models were fit.

17

19 Participants at non-dialysis stage 4 and those at stage 5 had lower HR-Hope scores than did

¹⁸ Results

1	those at stage 2 or 3 (combined). Those at non-dialysis stage 5 had the lowest scores.
2	HR-Hope scores of participants at stage 5D were similar to those of participants at stage 4,
3	but they were lower than the scores of participants at stage 2 or 3 (combined). Higher
4	HR-Hope scores were associated with lower perceived burdens of fluid restriction and of diet
5	restriction (adjusted ORs per ten-point difference were 0.82 and 0.84, respectively). Higher
6	HR-Hope scores were associated with lower systolic BP (adjusted mean difference in systolic
7	BP per ten-point difference in HR-Hope scores was -1.87 mmHg). In contrast, HR-Hope
8	scores were not associated with diastolic BP, serum phosphorus levels, or serum potassium
9	levels.
10	
11	Conclusions
12	Among CKD patients, HR-Hope is associated with disease stage, with psychological burden,
13	and with some physiological manifestations of adherence.
14	
15	
16	Keywords
17	adherence; diet restriction; fluid restriction; chronic kidney disease; health-related hope
18	
19	

1

2 Introduction

3	In patients with chronic kidney disease (CKD), mortality and cardiovascular
4	morbidity can be reduced. Specifically, they can be reduced if increases in blood pressure,
5	retention of fluid, and excessive accumulation of salt, potassium, and phosphorus are
6	prevented. Those goals can be achieved at least to some extent by adherence – both adherence
7	to prescriptions for medication and adherence to prescribed restrictions on the intake of fluids
8	and solid foods. (1, 2) Unfortunately, non-adherence appears to be quite common. (3) Results
9	of a qualitative study indicate that both non-adherence to prescribed medication intake and
10	non-adherence to prescribed fluid and dietary intake may be due in part to lack of motivation.
11	(2) Research on other chronic diseases identified at least one important source of motivation
12	for adherence: patients' hope. (4, 5)
13	Hope can be regarded as a goal-oriented way of thinking that enables people both to
14	find routes toward their goals and also to sustain their motivation to pursue those goals. (6, 7)
15	More than hope among healthy people, hope among patients with chronic illnesses is
16	concerned with health. (8) For patients with CKD, it is possible that adherence to
17	prescriptions for diet and medications can help them achieve their hoped-for goals. Thus,
18	CKD patients with greater health-related hope may better cope with the burdens of adherence
19	to those prescriptions, and as a result they might be better able to maintain relatively good

health. Despite this theoretical importance of hope in CKD patients, it has been studied only
 rarely. (9)

3	One analytical cross-sectional study of patients at CKD stage 5D showed that high
4	scores on Snyder's hope scale were associated with a lower burden of kidney disease as
5	measured using the KDQOL. (9) That study included only CKD patients who were
6	undergoing dialysis. Their symptoms were not correlated with scores on Snyder's hope scale
7	(which measures hope in general), but other likely correlates of hope, such as the severity of
8	CKD and physiological manifestations of adherence to prescribed medications and diet, were
9	not examined. (9) Patients' experiences of CKD vary with the stage of the disease: Patients
10	who have some hope for enjoying life have a tendency to adjust to their condition, or to
11	control it. (10) In this context, studies quantifying health-related hope, its relationships with
12	patients' experiences at different stages of CKD, and its associations with physiological
13	manifestations of adherence to prescribed medications and diet are likely to be clinically
14	relevant. Specifically, such studies might help patients and clinicians develop interventions to
15	increase hope and thereby promote adherence to those prescriptions.
16	To quantify the association of CKD stage with health-related hope, and the
17	association of that hope with psychological and physiological manifestations of adherence to
18	prescribed medications and diet, we used a recently developed scale to measure health-related
19	hope (HR-Hope) (11) and we analyzed cross-sectional data from a prospective cohort study:

1	the HOpe Trajectory and Disease Outcome Consortium (HOTDOC) for Japanese patients
2	with CKD.
3	
4	Methods
5	This was a multicenter cross-sectional study. The protocol was approved by the
6	ethics review boards of the local health authorities.
7	
8	Target population and settings
9	All of the participants were adults with CKD who were being treated by
10	nephrologists. Some did not require dialysis, while others had CKD stage 5D and were
11	receiving hemodialysis or peritoneal dialysis. Those with advanced cancer who were likely to
12	die within one year and those with psychiatric disease or dementia were not included. The
13	settings were one university hospital and four general hospitals. A total of 461 patients were
14	registered between February 2016 and September 2017.
15	
16	Study procedures.
17	Patients were asked to respond to the questionnaire after they gave informed consent.
18	The questionnaire included the HR-Hope scale, and selected items from the Japanese version
19	of the Kidney Disease Quality of Life (KDQOL) instrument.

1

2 Health-related hope scale (HR-Hope)

3	The HR-Hope scale measures hope among people with chronic diseases (Table S1
4	and S2). (11) The items use a 4-point Likert-type scale: I don't feel that way at all, I feel that
5	way a little, I feel that way somewhat, I strongly feel that way. The respondents are asked to
6	"Please answer the questions below while keeping in mind how you feel about your future
7	health prospects". Internal consistency reliability (coefficient alpha) was 0.93. Scores on the
8	HR-Hope scale were moderately correlated with scores on both domains of Snyder's hope
9	scale, (7, 12) and with scores on the 8 domains of the Medical Outcomes Study SF-36.(13) In
10	addition, the HR-Hope scale was more sensitive to change in socio-clinical status than was
11	Snyder's hope scale. For this study, the mean score of all 18 items was computed. For patients
12	without family, the 2 items related to family were not applicable, thus the scale score was
13	computed as the mean of the remaining 16 items. Next, the mean score was transformed to a 0
14	– 100 score.
15	
16	Exposures and outcomes: analytic framework

We examined how HR-Hope was associated with the psychological burden of CKD
and with physiological manifestations of adherence that are applicable across all stages of
kidney disease (see the conceptual framework in Fig. S1): (1-i) burden of fluid restriction,

1	(1-ii) burden of diet restriction, (2-i) systolic BP, (2-ii) diastolic BP, (3-i) serum phosphorus
2	levels, and (3-ii) serum potassium levels. Abnormalities in serum phosphorus and potassium
3	levels were taken as manifestations of non-adherence to prescribed diet. (14) Because
4	excessive fluid and salt intake, and skipping prescribed doses of anti-hypertensive
5	medications can contribute to BP elevation among CKD patients, abnormally high systolic
6	and diastolic BPs were taken as manifestations of non-adherence to prescriptions for
7	medications, fluid intake, and salt intake. Six categories of CKD were considered:
8	non-dialysis stage 2/3, non-dialysis stage 4, non-dialysis stage 5, dialysis for 1 year or less,
9	dialysis for >1 to 3 years, and dialysis for >3 years. The perceived burdens of fluid restriction
10	and diet restriction were assessed using items from the "Burden" subscale of the KDQOL.(15,
11	16) Participants were asked "How much does kidney disease bother you in each of the
12	following areas?" and the two areas considered were fluid restriction and dietary restriction.
13	The response choices were "Not at all bothered", "Somewhat bothered", "Moderately
14	bothered", "Very much bothered", and "Extremely bothered". Next, we examined whether
15	HR-Hope was associated with the stage of CKD and with key socio-demographic factors (see
16	the conceptual framework in Fig. S1).
17	
18	Covariates

Covariates used in the analyses included socio-demographic characteristics (age,

1	gender, presence of family, and working status), primary renal disease, comorbidities
2	(diabetes, coronary artery disease, and cerebrovascular disease), performance status (PS), and
3	medication (type of phosphate binder, number of phosphate binders prescribed, prescription
4	of potassium binder, class of antihypertensives prescribed, and total number of classes of
5	antihypertensives). Presence of family was asked with the item "Do you have any family?"
6	and the patients chose yes/no. Working status was asked using an item from KDQOL,(15, 16)
7	in which the patients answered yes/no to "During the past 4 weeks, did you work at a paying
8	job?". PS was assessed by the attending physician using scores developed by the Eastern
9	Cooperative Oncology Group (Zubrod Scale). (17) Possible scores range from 0 (normal
10	activity) to 4 (bedridden). A score of 2 (Ambulatory and capable of all self-care but unable to
11	carry out any work activities. Up and about more than 50% of waking hours.) or higher was
12	defined as impaired PS.
13	
14	Data collection
15	Medical data were collected from medical records by trained staff. Data on
16	socio-demographic factors, primary renal disease, dialysis duration (only for patients
17	receiving hemodialysis or peritoneal dialysis), comorbidities, medications, BP, and serum
18	phosphorus and potassium were extracted from medical records written at the time when the
19	participants received the questionnaires during their hospital visits. Among those receiving

1	hemodialysis, the data on BP and on serum phosphorus and potassium were those collected
2	routinely, before the first dialysis session of each week (typically before starting dialysis on a
3	Monday or a Tuesday).
4	
5	Statistical analysis
6	All statistical analyses were done using Stata/SE version 15 (Stata Corp., College
7	Station, TX). Socio-demographic characteristics, comorbidities, laboratory data, and
8	medication data were analyzed. The perceived burdens of fluid and diet restriction were
9	analyzed using generalized ordered logit models, (18) with and without adjustment for key
10	socio-demographic variables (adjusted model 1), and for variables in adjusted model 1
11	together with primary renal disease and comorbidities (adjusted model 2). (18) For these
12	analyses, the responses were collapsed into three categories: "Not at all bothered", "Somewhat
13	or Moderately bothered", and "Very much or Extremely bothered", and odds ratios for
14	increasing likelihood of degree of burden (at least "Somewhat or Moderately bothered" or at
15	least "Very much or Extremely bothered") were estimated.
16	The analytic models for systolic and diastolic BP were general linear models, with
17	and without adjustment for key socio-demographic variables (adjusted model 1), and for
18	variables in adjusted model 1, primary renal disease, comorbidities, and the number of classes
19	of prescribed antihypertensives (adjusted model 2). The analytic models for serum

1	phosphorus were general linear models, with and without adjustment for key
2	socio-demographic variables (adjusted model 1), and for variables in adjusted model 1,
3	primary renal disease, comorbidities, and the number of prescribed phosphate binders
4	(adjusted model 2). The analytic models for serum potassium were general linear models,
5	with and without adjustment for key socio-demographic variables (adjusted model 1), and for
6	variables in adjusted model 1, primary renal disease, comorbidities, and prescription of
7	potassium binders (adjusted model 2). The analytic models for HR-Hope were general linear
8	models, with and without adjustment for key socio-demographic variables (adjusted model 1),
9	and for variables in adjusted model 1 together with primary renal disease and comorbidities
10	(adjusted model 2). Within each analysis, all problems of missing data on covariates were
11	addressed by multiple imputation. (19) Five imputations were done using chained equations,
12	with the assumption that the data were missing at random. P values < 0.05 were taken as
13	indicators of statistical significance.
14	
15	Results
16	Participants
17	Characteristics of the 461 participants are shown in Table 1. About 10.2% of the participants
18	had impaired PS. Among the dialysis patients, about one third were receiving peritoneal
19	dialysis (32%). Compared with the non-dialysis patients, the dialysis patients were younger,

1	and they were more likely to have diabetic nephropathy, impaired PS, and higher systolic BP
2	and phosphorus levels. HR-Hope scores were normally distributed (Figure 1).
3	
4	Associations between HR-Hope and burdens
5	Figure 2 shows the distribution of perceived burden of fluid and dietary restrictions, by
6	quartile-defined categories of HR-Hope scores. Both burdens were lower among participants
7	with higher HR-Hope scores. Those associations were unchanged after adjustment for likely
8	confounders (adjusted OR per ten-point difference 0.82, 95%CI 0.73 to 0.92 for fluid
9	restriction, and 0.84, 95% CI 0.76 to 0.94 for dietary restriction, Table 2). Older participants
10	perceived fluid restriction as being less burdensome than did younger participants (adjusted
11	OR per ten-year difference 0.79, 95% CI 0.66 to 0.94). Employed participants perceived
12	dietary restriction as being more burdensome than did non-employed participants (adjusted
13	OR 1.88, 95%CI 1.20 to 2.94).
14	
15	Associations between HR-Hope and blood pressure
16	Participants with higher HR-Hope scores had lower systolic BP (mean difference per
17	ten-point difference -1.9 mmHg, 95%CI -3.1 to -0.7) (Table S2, Fig. 3). In contrast,
18	participants with higher HR-Hope scores had lower diastolic BP in the unadjusted analysis
19	(mean difference per ten-point difference -0.9 mmHg, 95%CI -1.8 to -0.1), but not after

- adjustment (mean difference per ten-point difference -0.6 mmHg, 95%CI -1.4 to 0.2).
- $\mathbf{2}$
- 3 Associations between HR-Hope and levels of phosphorus and potassium in serum
- 4 HR-Hope scores were not associated with the level of phosphorus or potassium in serum
- 5 (phosphorus: Table S4, Fig. 4A, potassium: Table S5, Fig. 4B).
- 6
- 7 Associations between disease stage and HR-Hope
- 8 HR-Hope scores were lower in participants at CKD stages 4 and 5 than in participants at CKD

9 stages 2 and 3 (Table 3, Fig. 5). After adjustment for likely confounders, being at a higher

- 10 stage of CKD was associated with having a lower HR-Hope score (Fig. 5; mean difference
- 11 -7.0 points, 95%CI -13.7 to -0.3 for stage 4, and -16.8 points, 95%CI -26.1 to -7.6, for stage
- 12 5). The difference in HR-Hope scores between participants at stage 4 and those at stage 2 or 3

13 was similar to the difference between participants who did and those who did not have family

- 14 (mean difference 7.7 points, 95% CI 2.3 13.1). The standardized effect sizes (Cohen's d) for
- 15 the differences between HR-Hope scores among participants at stage 4 and at stage 5 versus
- 16 those at stages 2 and 3 (combined), were 0.38 for stage 4 and 0.91 for stage 5. (20) Among
- 17 participants on dialysis, the HR-Hope scores were similar to the scores of those at stage 4, but
- they were lower than the scores of those at stage 2 or 3. Participants who had been receiving
- 19 dialysis for 1 year or less had lower HR-Hope scores than did those at CKD stage 2 or 3

1	(mean difference -7.9 points, 95%CI -14.4 to -1.4). While the HR-Hope scores of participants
2	who had been receiving dialysis for between 1 and 3 years were not lower than the scores of
3	those who were at stage 2 or 3 (mean difference -4.9 points, 95%CI -11.3 to 1.6), participants
4	who had been receiving dialysis for 3 years or longer had lower HR-Hope scores than did
5	those at CKD stage 2 or 3 (mean difference -8.8, 95%CI -14.5 to -3.2).
6	
7	
8	Discussion
9	We found that HR-Hope was greater among those patients who reported that fluid
10	restriction and dietary restriction were less burdensome. In addition, greater HR-Hope was
11	associated with lower systolic BP. Finally, HR-Hope was associated with disease stage: hope
12	was lowest among patients at non-dialysis stage 5, and it differed very little among the three
13	groups defined by the duration of dialysis. These findings highlight the importance of
14	integrating consideration of HR-Hope into clinical practice throughout the trajectory of CKD,
15	to achieve better adherence to prescriptions for diet and medication.
16	These findings may be useful to researchers and clinicians in several ways. First, the
17	finding that lower BP was associated with greater hope (as seen in the adjusted model for
18	systolic BP and in the unadjusted model for diastolic BP) suggests that hopeful patients may
19	more effectively adopt some self-management behaviors, resulting in better BP management.
20	Specifically, that association may have resulted from less salt intake or better adherence to

1	prescriptions for antihypertensive agents, as hopeful patients might be more likely to develop
2	strategies for dealing with their disease and for preventing it from worsening, both of which
3	are measured using the HR-Hope scale (Question 10 and Question 11 in Table S1 and S2).
4	Patients who have specific goals for their health may comprehend self-management behavior
5	as way to achieve their goals and thus they may implement healthy behavior in their daily life.
6	These notions are partially supported by the results of a previous study, which suggested that
7	dialysis patients who feel benefits from salt restriction actually consume less salt,(21) and
8	those who feel that they can control their health adhere more to prescriptions for medication.
9	(22) Second, hope was not associated with the levels of phosphorus or potassium in serum.
10	Because of the complexity of dietary management (knowledge about amounts of dietary
11	phosphorus and potassium) and simultaneous considerations of family relationships and
12	household income, (2, 23) choosing foods that contain only small amounts of phosphorus and
13	potassium may be difficult. Family relationships can help to support healthy food choices and
14	cooking, but can also interfere with patients' self-management. (2) Patients who were
15	employed reported feeling a greater burden of dietary restrictions than did those who were not
16	employed. This could reflect employed patients' difficulty in meal-related socializing. When
17	they gather with work colleagues over lunch or dinner, which is important for maintaining
18	business connections and work-group solidarity, (24) CKD patients may feel obliged to eat as
19	other people do. (25) Third, HR-Hope is potentially modifiable by psychosocial interventions.

1	For example, individualized counseling can be aimed at increasing hope. In one study of
2	hemodialysis patients, a well-organized, regular counseling program helped those patients to
3	frame their hope during their illness and to find ways to reduce anxiety and stress. (26) Fourth,
4	we found that hope was at its minimum among patients at stage 5 CKD, that is, among
5	patients whose disease was so severe that they almost needed dialysis. Also, to the extent that
6	a longitudinal trend can be inferred from data obtained cross-sectionally from patients who
7	had undergone dialysis for different lengths of time (Figure 5), we found that hope was
8	relatively stable over more than 3 years of dialysis therapy. Those two findings suggest that
9	chronicity of disease course might also affect HR-Hope. As renal function deteriorates,
10	HR-Hope might decrease because of anxiety and fear of an imminent lifelong dependence on
11	dialysis, and of burdensome symptoms of uremia such as pulmonary edema, decreased
12	appetite, malaise, and pruritus. While starting dialysis may alleviate symptoms of uremia,
13	patients are forced to adjust their lives to their therapy (i.e. thrice-weekly visits to a dialysis
14	center for those undergoing hemodialysis and every day at home for those undergoing
15	peritoneal dialysis) and to a strict dietary and fluid-intake regimen, and thus they may have
16	less HR-Hope than do patients who are still at stage 2 or 3 of CKD. Our observation that low
17	levels of hope persist during the first 12 months of both hemodialysis and peritoneal dialysis
18	concurs to some degree with previous studies focusing on 12-month change in health-related
19	QOL of dialysis patients. (27, 28)

1	Several strengths of this study should be noted. First, we showed that HR-Hope is
2	associated with objective manifestations of adherence to prescriptions for diet and
3	medications. In contrast, a previous study of hope in general (not HR-Hope) found no
4	association of hope with physical functioning or with symptoms and problems related to
5	kidney disease. (9) Second, previously only hope in general had been studied (using Snyder's
6	hope scale), and then only among patients at stage 5D.(9) In contrast, we found quantitative
7	differences in HR-Hope across a wide range of severity-defined categories of CKD.
8	Several limitations of this study also warrant mention. First, because the study was
9	cross-sectional, we cannot infer causal relationships from the associations of HR-Hope with
10	the stage of kidney disease, or with objective manifestations of adherence. Patients with high
11	systolic BP might struggle with the responsibility of taking multiple antihypertensive agents
12	and following dietary instructions, and thus they might find fluid restriction and dietary
13	restriction to be very burdensome, which might cause them to have little or no hope. Second,
14	we were not able to quantify adherence itself by measuring, for example, intake of salt,
15	phosphorus, and potassium, or by counting the numbers of prescribed doses of medications
16	that patients did and did not take. Nonetheless, it may be argued that the objective indices we
17	used are at least as important clinically as adherence itself. Third, HR-Hope may be affected
18	by spiritual and religious factors. This could be important in some countries, but we believe
19	that any effects it might have had on the differences we found in this study are negligible, as

1	all of the participants were Japanese, among whom few regularly engage in religious
2	activities.
3	
4	Conclusions
5	Throughout the trajectory of CKD, HR-Hope changed with disease stage. It was
6	lowest at non-dialysis stage 5, followed by stages 4 and 5D. Health-related hope was
7	associated with the patient-perceived burden of fluid and dietary restriction, and also with
8	some objective manifestations of adherence to prescriptions for diet and medications.
9	Therefore, nephrologists and dieticians should consider interventions for increasing HR-Hope
10	to promote self-care and improve CKD patients' adherence to those prescriptions.
11	
12	Declarations
13	Ethics approval and consent to participate
14	This study was conducted in accordance with the Declaration of Helsinki. This study was
15	approved by the ethics review boards of St. Marianna University School of Medicine
16	(No.3209) and Fukushima Medical University (No.2417). Written consent was obtained.
17	
18	Consent for publication
19	Not applicable.

1

2 Availability of data and materials

3 The datasets used and/or analyzed during the current study are available from the
4 corresponding author on reasonable request.
5

- 6
- 7 Acknowledgements
- 8 The authors greatly thank the following researchers, research assistants, and medical
- 9 staff members for their assistance in collecting the questionnaire-based and clinical
- 10 information used in this study: Ms. Asako Tamura, Ms. Yuka Masuda, Ms. Takae Shimizu (St.
- 11 Marriana University, Kawasaki-city, Kanagawa), Takayuki Nakamura, MD, Eiko Hashimoto,
- 12 RN (JCHO Nihonmatsu Hospital, Nihonmatsu-city, Fukushima), Atsushi Kyan, MD, Masashi
- 13 Saito, CE (Shirakawa Kosei General Hospital, Shirakawa-city, Fukushima), Ms. Lisa
- 14 Shimokawa (Fukushima Medical University Hospital, Fukushima-city, Fukushima).
- 15

- 17 Competing interests
- 18 NK, TW, YI, S.Fujimoto, M. Yazawa, TS, KK, M. Yanagi, HK, JG, S.Fukuhara, and YS
- 19 declare that they have no relevant financial interests.

1

2	Authors'	contributions
-	riguioro	contributions

3	Contributions: research idea and study design: NK, TW, YI, S. Fukuhara, YS; data
4	acquisition: NK, YI, S. Fujimoto, M Yazawa, TS, KK, M Yanagi, HK ; data analysis and
5	interpretation: NK, TW, YI, JG, S. Fukuhara, YS; statistical analysis: NK; supervision or
6	mentorship: YI, JG, S. Fukuhara, YS. Each author contributed important intellectual content
7	during article drafting or revision and accepts accountability for the overall work by ensuring
8	that questions pertaining to the accuracy or integrity of any portion of the work are
9	appropriately investigated and resolved.
10	
11	Funding
12	This study was supported by JSPS KAKENHI (Grant Number: JP16H05216). The funders
13	had no role in the study design, analysis, or interpretation of data; writing of the manuscript;
14	or the decision to submit the manuscript for publication.
15	
16	
17	References
18	1. Kurita N, Hayashino Y, Yamazaki S, Akizawa T, Akiba T, Saito A, et al. Revisiting

19 Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The

1 Japanese Dialysis Outcomes and Practice Pattern Study. Jrounal of Renal Nu	trition.
--	----------

2	2017;27(6):421-9.
---	-------------------

3	2. Palmer SC, Hanson CS, Craig JC, Strippoli GF, Ruospo M, Campbell K, et al.
4	Dietary and fluid restrictions in CKD: a thematic synthesis of patient views from qualitative
5	studies. American journal of kidney diseases : the official journal of the National Kidney
6	Foundation. 2015;65(4):559-73.
7	3. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, et al.
8	Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice
9	patterns in the DOPPS. Kidney international. 2003;64(1):254-62.
10	4. Berg CJ, Rapoff MA, Snyder CR, Belmont JM. The relationship of children's hope to
11	pediatric asthma treatment adherence. The Journal of Positive Psychology. 2007;2(3):176-84.
12	5. Santos FR, Sigulem D, Areco KC, Gabbay MA, Dib SA, Bernardo V. Hope matters
13	to the glycemic control of adolescents and young adults with type 1 diabetes. Journal of
14	Health Psychology. 2015;20(5):681-9.
15	6. Buchanan CL, Lopez SJ. Understanding Hope in Individuals with Disabilities. In:
16	Wehmeyer ML, editor. The Oxford Handbook of Positive Psychology and Disability: Oxford
17	University Press; 2013. pp. 154-65.
18	7. Snyder CR, Harris C, Anderson JR, Holleran SA, Irving LM, Sigmon ST, et al. The
19	will and the ways: development and validation of an individual-differences measure of hope. J

1 Pers Soc Psychol. 1991;60(4):570-85.
-------------------------------	-----------

2	8. Wakita T, Kurita N, Tominaga N, Kato K, Konno S, Fukuhara S, et al. Hope in Adult
3	Patients with Chronic Disease: Qualitative Study. Kansai Univ Psychol Res. 2016(7):17-33
4	(in Japanese except for English abstract).
5	9. Billington E, Simpson J, Unwin J, Bray D, Giles D. Does hope predict adjustment to
6	end-stage renal failure and consequent dialysis? British Journal of Health Psychology.
7	2008;13(4):683-99.
8	10. Teasdale EJ, Leydon G, Fraser S, Roderick P, Taal MW, Tonkin-Crine S. Patients'
9	Experiences After CKD Diagnosis: A Meta-ethnographic Study and Systematic Review.
10	American Journal of Kidney Diseases. 2017;70(5):656-65.
11	11. Fukuhara S, Kurita N, Wakita T, Green J, Shibagaki Y. A scale for measuring
12	Health-Related Hope: its development and psychometric testing. Annals of Clinical
13	Epidemiology. 2019;1(3):102-19.
14	12. Kato T, Snyder CR. The relationship between hope and subjective well-being:
15	Reliability and validity of the dispositional Hope Scale, Japanese version. Jpn J Psychol.
16	2005;76(3):227-34 (in Japanese).
17	13. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and
18	validation of the SF-36 Health Survey for use in Japan. Journal of clinical epidemiology.
19	1998;51(11):1037-44.

1	14. Denhaerynck K, Manhaeve D, Dobbels F, Garzoni D, Nolte C, De Geest S.
2	Prevalence and consequences of nonadherence to hemodialysis regimens. American Journal
3	of Critical Care. 2007;16(3):222-35.
4	15. Green J, Fukuhara S, Shinzato T, Miura Y, Wada S, Hays R, et al. Translation,
5	cultural adaptation, and initial reliability and multitrait testing of the Kidney Disease Quality
6	of Life instrument for use in Japan. Quality of Life Research. 2001;10(1):93-100.
7	16. Miura Y, Green J, Fukuhara S. Manual of the KDQOL Japanese version 1.3. Institute
8	for Health Outcomes & Process Evaluation Research, Kyoto. 2004.
9	17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.
10	Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.
11	1982;5(6):649-56.
12	18. Williams R. Generalized ordered logit/partial proportional odds models for ordinal
13	dependent variables. Stata Journal. 2006;6(1):58.
14	19. van der Heijden GJMG, T. Donders AR, Stijnen T, Moons KGM. Imputation of
15	missing values is superior to complete case analysis and the missing-indicator method in
16	multivariable diagnostic research: A clinical example. Journal of clinical epidemiology.
17	2006;59(10):1102-9.
18	20. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T.
19	Estimating clinically significant differences in quality of life outcomes. Quality of life

- 1 research : an international journal of quality of life aspects of treatment, care and
- 2 rehabilitation. 2005;14(2):285-95.
- 3 21. Agondi RdF, Gallani M-CBJ, Rodrigues RCM, Cornélio ME. Relationship Between
- 4 Beliefs Regarding a Low Salt Diet in Chronic Renal Failure Patients on Dialysis. Journal of
- 5 Renal Nutrition. 2011;21(2):160-8.
- 6 22. Theofilou P. Medication Adherence in Greek Hemodialysis Patients: The
- 7 Contribution of Depression and Health Cognitions. International Journal of Behavioral
- 8 Medicine. 2013;20(2):311-8.
- 9 23. Backman DR, Haddad EH, Lee JW, Johnston PK, Hodgkin GE. Psychosocial
- 10 Predictors of Healthful Dietary Behavior in Adolescents. Journal of Nutrition Education and
- 11 Behavior. 2002;34(4):184-93.
- 12 24. Lam LW, Twinn SF, Chan SWC. Self-reported adherence to a therapeutic regimen
- 13 among patients undergoing continuous ambulatory peritoneal dialysis. Journal of Advanced
- 14 Nursing. 2010;66(4):763-73.
- 15 25. Griva K, Ng HJ, Loei J, Mooppil N, McBain H, Newman SP. Managing treatment for
- 16 end-stage renal disease A qualitative study exploring cultural perspectives on facilitators and
- barriers to treatment adherence. Psychology & Health. 2013;28(1):13-29.
- 18 26. Rahimipour M, Shahgholian N, Yazdani M. Effect of hope therapy on depression,
- anxiety, and stress among the patients undergoing hemodialysis. Iranian journal of nursing

- 1 and midwifery research. 2015;20(6):694-9.
- 2 27. Broers NJH, Martens RJH, Canaud B, Cornelis T, Dejagere T, Diederen NMP, et al.
- 3 Health-related quality of life in end-stage renal disease patients: the effects of starting dialysis
- 4 in the first year after the transition period. International Urology and Nephrology.
- 5 2018;50(6):1131-42.
- 6 28. Lim HA, Yu Z, Kang AWC, Foo MWY, Griva K. The Course of Quality of Life in
- 7 Patients on Peritoneal Dialysis: A 12-month Prospective Observational Cohort Study.
- 8 International Journal of Behavioral Medicine. 2016;23(4):507-14.
- 9

Table 1. Characteristics of analysis				D ! 1 !	D ! 1 !	5.1.	— 1
	Non-dialysis	Non-dialysis	Non-dialysis	Dialysis	Dialysis	Dialysis	Total
	Stage 2/3	Stage 4	Stage 5	0 to 1 yr	>1 to 3yr	>3 yr	
	n = 59	n = 55	n = 19	n = 66	n = 72	n = 190	n = 461
Dialysis modality, % ^a							
Hemodialysis				71.2%	52.8%	72.6%	68.0%
Peritoneal dialysis				28.8%	47.2%	27.4%	32.0%
eGFR, mL/min/1.73 m ²	46.1	22.4	11.5	6.9	5.0	4.0	12.5
	(12.3)	(4.3)	(2.8)	(2.7)	(2.1)	(1.5)	(15.0)
Age, yr	70.7	74.5	73.9	66.8	64.9	64.3	67.2
	(12.7)	(12.5)	(9.2)	(15.5)	(15.5)	(12.7)	(13.9)
Women, %	33.9%	30.9%	36.8%	27.3%	22.2%	36.3%	31.9%
Renal disease, %							
Diabetic nephropathy	5.1%	21.8%	15.8%	30.3%	43.1%	26.8%	26.0%
Glomerulonephritis	13.6%	12.7%	21.1%	25.8%	23.6%	34.2%	25.6%
Nephrosclerosis	37.3%	32.7%	31.6%	27.3%	15.3%	6.8%	19.1%
Polycystic kidney	0.0%	0.0%	5.3%	7.6%	1.4%	7.9%	4.8%
Others/Unknown	44.1%	32.7%	26.3%	9.1%	16.7%	24.2%	24.5%
Impaired performance status, %	1.7%	5.5%	5.3%	13.6%	6.9%	14.7%	10.2%
Diabetes, %	18.6%	45.5%	31.6%	43.9%	50.0%	33.2%	36.9%
Cerebrovascular disease, %	6.8%	16.4%	15.8%	16.7%	16.7%	12.1%	13.5%
Coronary artery disease, %	3.4%	23.6%	15.8%	16.7%	15.3%	16.8%	15.6%
SBP, mmHg	130	133	142	139	143	145	141
	(17)	(17)	(20)	(22)	(24)	(28)	(25)
Missing	12	11	5		1		29
DBP, mmHg	79	69	72	75	75	79	77

Table 1 Characteristics of analysis nonulation 1

Missing	(12) 23	(14) 21	(12) 5	(15)	(15)	(17)	(16) 50
Phosphorus, mg/dL	3.2 (0.4)	3.6 (0.5)	4.0 (0.7)	5.3 (1.5)	5.4 (1.3)	5.5 (1.4)	5.0 (1.5)
Missing	31	5		~ /	~ /	1	37
Potassium, mEq/L	4.4 (0.3)	4.8 (0.6)	4.7 (0.5)	4.4 (0.7)	4.4 (0.7)	4.7 (0.8)	4.6 (0.7)
Missing	3					2	5
N of categories of antihypertensive drugs, %							
None	39.0%	14.6%	15.8%	21.2%	23.6%	38.4%	29.9%
1	33.9%	29.1%	26.3%	28.8%	23.6%	25.8%	27.3%
2	20.3%	32.7%	52.6%	31.8%	34.7%	21.1%	27.3%
3 or more	6.8%	23.6%	5.3%	18.2%	18.1%	14.7%	15.4%
N of phosphate binder, %							
None	100.0%	100.0%	89.5%	68.2%	30.6%	16.3%	49.7%
1 to 5	0.0%	0.0%	10.5%	18.2%	25.0%	19.5%	15.0%
6 to 10	0.0%	0.0%	0.0%	13.6%	27.8%	41.6%	23.4%
11 to 15	0.0%	0.0%	0.0%	0.0%	9.7%	15.8%	8.0%
16 or over	0.0%	0.0%	0.0%	0.0%	6.9%	6.8%	3.9%
Prescription for potassium binder, %	1.7%	16.4%	5.3%	3.0%	13.9%	23.7%	14.8%

For continuous variable, data were summarized as mean and standard deviation in parenthesis.

^aCalculated only among dialysis patients.
 eGFR: estimated glomerular filtration rate

eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; diastolic blood pressure

4

	Fluid re	estriction ($n = 444$),	OR (95%CI)	Diet restriction ($n = 444$), OR (95%CI)			
	Unadjusted	Adjusted 1 ^b	Adjusted 2 ^c	Unadjusted	Adjusted 1 ^b	Adjusted 2 ^c	
HR-Hope							
per 10 points	0.79 (0.71 – 0.87)	0.83 (0.74 - 0.93)	0.82 (0.73 - 0.92)	0.84 (0.76 - 0.93)	0.85 (0.77 – 0.95)	0.84 (0.76 - 0.94)	
per 1 SD	0.65 (0.54 - 0.78)	0.71 (0.58 – 0.87)	0.69 (0.56 - 0.85)	0.72 (0.60 - 0.87)	0.74 (0.61 - 0.90)	0.73 (0.60 - 0.89)	
Age, yr per 10 yr	-	0.80 (0.68 - 0.95)	0.79 (0.66 - 0.94)	-	0.91 (0.78 – 1.06)	0.88 (0.75 – 1.03)	
Presence of family, yes	-	0.96 (0.51 – 1.80)	1.02 (0.53 – 1.97)	-	1.12 (0.62 – 2.02)	1.16 (0.63 – 2.15)	
Working, yes	-	1.11 (0.69 – 1.79)	1.13 (0.69 – 1.85)	-	1.80 (1.16 - 2.79)	1.88 (1.20 – 2.94)	

1 Table 2. Associations between HR-Hope, key demographic factors, and degree of burdens of fluid or diet restriction.^a

^aGeneralized ordered logit models were used to estimate odds ratios for increasing degree of burdens.

^bAdjusted for age, gender, stage of renal disease, performance status, presence of family, and working status.

⁴ ^cAdjusted for the covariates listed in footnote b, and also for primary renal disease, diabetes, coronary artery disease, and cerebrovascular disease.

HR-Hope: health-related hope; OR: odds ratio; 95%CI: 95% Confidence interval.

 $\frac{5}{6}$

 $\mathbf{2}$

	HR-Hope (n =	458), Mean difference,	points (95%CI)
	Unadjusted	Adjusted 1 ^b	Adjusted 2 ^c
Stage of kidney disease (vs. non-dialysis stage 2/3)	Ref.	Ref.	Ref.
non-dialysis Stage 4	-7.1	-7.5	-7.0
	(-13.8 – -0.4)	(-14.20.9)	(-13.70.3)
non-dialysis Stage 5	-16.2	-17.2	-16.8
	(-25.66.7)	(-26.58.0)	(-26.17.6)
dialysis, >0 to 1 yr	-11.8	-9.1	-7.9
	(-18.3 – -5.4)	(-15.5 – -2.7)	(-14.4 – -1.4)
dialysis, >1 to 3 yr	-9.5	-6.6	-4.9
	(-15.83.2)	(-12.90.3)	(-11.3 – 1.6)
dialysis, >3 yr	-12.5	-10.1	-8.8
	(-17.9 – -7.1)	(-15.5 – -4.6)	(-14.5 – -3.2)
Age, yr	-	2.3	2.1
per 10 yr		(1.0 - 3.7)	(0.7 - 3.5)
Presence of family, yes	-	7.5 (2.2 – 12.9)	7.7 (2.3 – 13.1)
Working, yes	-	1.3	1.0

1 Table 3. Associations between stage of kidney disease, key demographics, and levels of health-related hope.^a

(-2.6 - 5.2) (-2.9 - 4.9)

^aGeneral linear models were used to estimate mean differences in health-related hope scores.

² ^bAdjusted for age, gender, stage of kidney disease, performance status, presence of family, and working status.

³ ^cAdjusted for the covariates listed in footnote b, and also for primary renal disease, diabetes, coronary artery disease, and cerebrovascular disease.

4 HR-Hope: health-related hope; 95%CI: 95% Confidence interval.

 $\frac{5}{6}$

0	0
	~
υ	υ

Legend to figures 1

- $\mathbf{2}$
- 3 Figure 1. Distribution of HR-Hope scores
- 4
- Figure 2. The distributions of degree of burdens of fluid or diet restriction by quartiles of 5

6 HR-Hope score.

 $\overline{7}$ Figure 2A shows distributions of perceived burden of fluid restriction. Figure 2B shows

- 8 distributions of perceived burden of diet restriction. Vertical axes indicate proportions of
- 9 responses. Numbers in each bar graph indicate absolute numbers of responses (n = 444).
- 10 HR-Hope: health-related hope.
- 11
- 12Figure 3. Associations between HR-Hope and blood pressure.
- 13 Red squares: unadjusted models. Blue circles: models adjusted for age, sex, performance
- 14status, presence of family, working status, and number of categories of prescribed
- 15antihypertensives (adjusted model 1). Green triangles: models adjusted for all of the variables
- 16 listed above, and also for primary renal disease, diabetes, coronary artery disease, and
- 17cerebrovascular disease (adjusted model 2).

18

19Mean differences estimated via general linear models (n = 429 for systolic BP and n = 408 for

20	diastolic BP). Error	· bar indicate	95%	confidence	intervals
----	--------------	----------	----------------	-----	------------	-----------

21HR-Hope: health-related hope; SBP: systolic blood pressure, DBP: diastolic blood pressure 22

- 23Figure 4. Associations between HR-Hope and serum phosphorus or potassium levels.
- 24Figure 4A: Association between HR-Hope and serum phosphorus. Red squares: unadjusted
- 25models. Blue circles: models adjusted for age, sex, performance status, presence of family,

1	working status, and number of categories of prescribed phosphate binders (adjusted model 1).
2	Green triangles: models adjusted for all of the variables listed above, and also for primary
3	renal disease, diabetes, coronary artery disease, and cerebrovascular disease (adjusted model
4	2).
5	Figure 4B: Association between HR-Hope and serum potassium. Red squares: unadjusted
6	models. Blue circles: models adjusted for age, sex, performance status, presence of family,
7	working status, and number of categories of prescribed potassium binders (adjusted model 1).
8	Green triangles: models adjusted for all of the variables listed above, and also for primary
9	renal disease, diabetes, coronary artery disease, and cerebrovascular disease (adjusted model
10	2).
11	Mean differences estimated via general linear models ($n = 422$ for phosphorus and $n = 453$ for
12	potassium). Error bars indicate 95% confidence intervals.
13	HR-Hope: health-related hope; P: phosphorus, K: potassium
14	
15	Figure 5. Association between stage of kidney disease and HR-Hope scores.
16	Red squares: unadjusted models. Blue circles: models adjusted for age, sex, performance
17	status, presence of family, and working status (adjusted model 1). Green triangles: models
18	adjusted for all of the variables listed above, and also for primary renal disease, diabetes,
19	coronary artery disease, and cerebrovascular disease (adjusted model 2).
20	Vertical axis indicates mean difference in HR-Hope scores. Error bars indicate 95%
21	confidence intervals. The stages of kidney disease shown here are non-dialysis stages 2 and 3
22	(combined), which is the reference category, non-dialysis stage 4, non-dialysis stage 5, stage
23	5D with dialysis duration no longer than 1 year, stage 5D with dialysis duration greater than 1
24	but no longer than 3 years, and stage 5D with dialysis duration greater than 3 years.
25	Mean differences estimated via general linear models ($n = 458$).


1	HR-Hope: health-related hope
---	------------------------------


 $\mathbf{2}$

3 Titles of supplementary material

- 4 Table S1. English version of the 18-item Health-Related Hope scale.
- 5 Table S2. Japanese version of the 18-item Health-Related Hope scale.
- 6 Figure S1. Conceptual framework used in regression analyses.
- 7 Table S3. The associations between HR-Hope and blood pressures.
- 8 Table S4. The associations between HR-Hope and serum phosphorus levels.
- 9 Table S5. The associations between HR-Hope and serum potassium levels







1 Figure 2



